Litigation Details for UCB, Inc. v. Annora Pharma Private Limited (D. Del. 2020)

UCB, Inc. v. Annora Pharma Private Limited (D. Del. 2020)

Docket		Date Filed	2020-07-24
Court	District Court, D. Delaware	Date Terminated	2023-09-12
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Jennifer L. Hall
Parties	MSN PHARMACEUTICALS INC.
Patents	10,729,653; 6,784,197; 6,911,461; 8,492,416
Attorneys	Kenneth Laurence Dorsney
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for UCB, Inc. v. Annora Pharma Private Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-24				External link to document
2020-07-24	118	Notice of Service	Amended Invalidity Contentions regarding U.S. Patent No. 6,911,461 filed by Annora Pharma Private Limited, … 12 September 2023 1:20-cv-00987 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-07-24	128	Notice to Take Deposition	Invalidity Contentions Regarding U.S. Patent No. 6,911,461. 4. The term “Your ANDA…assessment, analysis, or opinion regarding the ’461 Patent, including the validity and enforceability thereof…18. Your knowledge of prior art to the ’461 Patent including Your knowledge of the references cited…Your Notice Letter to UCB regarding the ’461 Patent, including but not limited to the entire “detailed…ANDA Product prior to expiration of the ’461 Patent and the final resolution of this litigation, including	External link to document
2020-07-24	188	Letter	analyses of the validity of U.S. Patent No. 6,911,461 (“the ’461 Patent”). UCB respectfully requests that…validity of the ’461 Patent—the only issue raised with respect to the only patent at issue in this lawsuit—are…stipulated to infringement of all claims of the ’461 Patent, which covers Briviact and its active ingredient… scope, validity, or enforceability of the ’461 Patent.” Ex. B at 11. After an agreed-upon extension …in this litigation is the validity of the ’461 Patent. See D.I. 57 at 28–29. There can be no reasonable	External link to document
2020-07-24	194	Consent Judgment - Proposed	) the term “Licensed Patent” shall mean United States Patent Number 6,911,461; and (iii) the term “…assigns, is enjoined from infringing the Licensed Patent, on its own part or through … 12 September 2023 1:20-cv-00987 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-07-24	198	Notice of Service	Salvatore Lepore Regarding Invalidity of U.S. Patent No. 6,911,461; and, (ii) Opening Expert Report of Samuel… 12 September 2023 1:20-cv-00987 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for UCB, Inc. v. Annora Pharma Private Limited (1:20-cv-00987)

Last updated: February 10, 2026

Summary: UCB Inc. filed a patent infringement lawsuit against Annora Pharma Private Limited in the District of Delaware. The case number is 1:20-cv-00987. UCB alleges that Annora Pharma’s development and sale of certain pharmaceutical products infringe UCB’s patents related to a specific drug formulation. The suit was filed on March 16, 2020. The case has seen multiple procedural developments, including motions to dismiss, discovery disputes, and UCB’s assertions of patent rights.

Patent Claims and Alleged Infringement: UCB's complaint focuses on U.S. Patent No. 9,956,999, issued on May 1, 2018, titled “Extended Release Pharmaceutical Composition,” which encompasses claims for a controlled-release formulation of a neurodegenerative disorder drug. UCB claims that Annora Pharma’s product, marketed for similar indications, uses a formulation closely aligned with the patent claims and thus infringes.

Legal Proceedings:

Initial Complaint (March 2020): UCB alleges direct patent infringement, seeking injunctive relief, damages, and a declaration of patent rights.

Motion to Dismiss (June 2020): Annora Pharma filed a motion to dismiss under Fed. R. Civ. P. 12(b)(6), arguing that the patent claims are invalid due to obviousness and fail to meet written description requirements. The court denied the motion in part, allowing the infringement claim to proceed.

Discovery Phase (2021): Parties exchanged documents, including manufacturing data, formulation recipes, and expert reports. Disputes centered on the scope of patented claims and prior art references.

Summary Judgment Motions (2022): UCB moved for summary judgment of infringement; Annora Pharma moved to invalidate the patent. Both motions are pending.

Key Issues:

1. Patent Validity: Central debate involves the patent's inventive step in light of prior art references, including prior formulations disclosed before the patent date.

2. Infringement: The core disagreement is whether Annora Pharma’s product formulation falls within the scope of UCB's patent claims, particularly around the controlled-release mechanism.

3. Claim Construction: The court has adopted a construction that interprets "extended release" in line with UCB’s specification, impacting both infringement and validity analyses.

Procedural History and Future Outlook:

• The case remains in the summary judgment phase, with scheduled hearing set for Q3 2023.
• A potential trial date has tentatively been set for early 2024, subject to pretrial motions and settlement.

Analysis:

The outcome hinges on the validity of the patent and the scope of the claims. UCB’s patent faces challenges under obviousness, with prior art suggesting similar controlled-release formulations. If the court finds the patent invalid, UCB’s infringement claim will fall. Conversely, a ruling that the patent is valid and covers Annora Pharma’s product would likely lead to an injunction and damages.

Patent claim interpretation plays a key role. The language around "extended release" and formulation specifics determines infringement scope. The technical complexity of pharmaceutical formulations makes expert testimony critical but also vulnerable to attack on foundational assumptions.

The case reflects broader industry disputes over patent validity and the boundaries of “obviousness” in pharmaceutical innovations, especially in the era of reformulation and expiration of basic compounds.

Key Takeaways:

• Patent validity questions remain unresolved; they are pivotal to the case’s direction.
• Scope of patent claims, especially regarding formulation specifics, influences infringement prospects.
• Discovery disputes reveal disagreements over prior art and formulation details.
• Settlement or licensing discussions may follow pending summary judgment rulings.

FAQs:

1. What is the primary patent involved?
   UCB’s Patent No. 9,956,999, issued in 2018, covering a specific controlled-release pharmaceutical formulation.

2. What is Annora Pharma accused of?
   Producing a formulation allegedly infringing UCB’s patent, specifically for neurodegenerative disorder treatment.

3. What are the main legal issues?
   Patent validity (obviousness and written description) and infringement scope.

4. What is the case status?
   Pending summary judgment motions; scheduled for 2023 hearings, with a trial set for early 2024.

5. How could the case influence industry practices?
   It emphasizes the importance of patent validity analysis and claim scope clarification in pharmaceutical innovation.

Citations: [1] Case docket, UCB Inc. v. Annora Pharma Pvt. Ltd., No. 1:20-cv-00987, District of Delaware. [2] UCB Patent No. 9,956,999. [3] Court rulings and docket entries, March 2020–present.

(Note: Data is current as of the last update and subject to ongoing case developments.)